Compared to monotherapy with chemotherapy, ICIs targeting the PD-1 axis have demonstrated significantly improved patient survival rates in first-line or second-line treatment for advanced NSCLC, whether used alone or in combination with chemotherapy (4). Here, PDCD1 is linked to non-small cell lung carcinoma.